成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

利拉魯肽,Liraglutide
  • 利拉魯肽,Liraglutide

利拉魯肽

價(jià)格 詢(xún)價(jià)
包裝 5kg 10kg
最小起訂量 5kg
發(fā)貨地 浙江
更新日期 2021-03-26

產(chǎn)品詳情

中文名稱(chēng):利拉魯肽英文名稱(chēng):Liraglutide
CAS:204656-20-2純度規(guī)格: 99.7%
產(chǎn)品類(lèi)別: 原料藥與中間體
備注: US-DMF Pre-assigned
2021-03-26 利拉魯肽 Liraglutide 5kg/RMB;10kg/RMB 99.7% 原料藥與中間體

Product Name: Liraglutide

Synonym:Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

 

MF:C172H265N43O51

MW:3751.202

Product Category: GLP

 

Pharmacodynamic and Pharmacology Properties: Liraglutide is an acylated GLP-1 analogue that shares 97 % amino acid sequence homology to human endogenous GLP-1 (7–37). The single amino acid substitution of lysine with arginine at position 34 and the attachment of a C16 fatty acid chain to lysine at position 26 enables liraglutide to self-associate and form a heptameric structure, which delays absorption from the subcutaneous injection site and provides protection against degradation by DPP-4 enzyme and neutral endopeptidases. As a consequence, liraglutide has a much longer half-life than endogenous GLP-1 (&13 h vs. 1.5–2 min).

Liraglutide binds to and activates the GLP-1 receptor, which is a membrane bound cell-surface receptor coupled to adenyl cyclase by the stimulatory G-protein (Gs) in pancreatic b cells (but not in pancreatic a-cells) and is the target for endogenous GLP-1. This results in increased intracellular cyclic monophosphate and subsequent liraglutide dose-dependent insulin release in patients with elevated glucose levels. At the same time, liraglutide acts in a glucose-dependent manner to decrease inappropriately high glucagon secretion, thereby blocking the effects of glucagon on hepatic glucose output. In the presence of liraglutide, as blood glucose concentrations decrease, the secretion of insulin diminishes and blood glucose concentrations approach euglycaemia. In addition to these glucoregulatory mechanisms of action in patients with type 2 diabetes, liraglutide slightly delays gastric emptying, and reduces bodyweight and body fat mass by reducing hunger and lowering energy intake; these effects may contribute to the beneficial effects of liraglutide in patients with type 2-diabetes. As reviewed previously, in patients with type 2 diabetes and/or in preclinical studies, liraglutide dosedependently reduced glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial plasma glucose levels, with sustained improvements in glucose levels over a 24-h dosage interval. In addition, liraglutide increased insulin secretion, reduced postprandial glucagon secretion, improved surrogate measures of b-cell function, reduced systolic blood pressure (SBP) and improved some biomarkers of cardiovascular (CV) risk in patients with type 2 diabetes, including suppression of postprandial triglyceride and apolipoprotein B48 levels after a fat-rich meal. Improvements in glycaemic control and other efficacy outcomes in adult patients with type 2 diabetes receiving liraglutide monotherapy or add-on therapies to other antidiabetic drugs in large phase III trials.

Description: Approaches to treating T2DM, a disease characterized by the dual defect of islet cell dysfunction and insulin resistance, include agents that increase the secretion of insulin by the pancreas (secretagogues), agents that increase the sensitivity of target organs to insulin (sensitizers), and agents that decrease the glucose absorption rate from the gastrointestinal tract.Liraglutide, the GLP-1 receptor agonist to reach the market, possesses a 97% homology to GLP-1 with only two amino acid changes and the addition of a fatty acid side chain. Specifically, the lysine in position 34 has been replaced with an arginine, and the lysine in position 26 has been modified with a C16 acyl chain via a glutamoyl spacer. Liraglutide derives its resistance to DPP-4 degradation from its propensity to form micelles and to bind to albumin. Unlike its predecessor exenatide, which requires two daily subcutaneous injections before the first and last meals of the day, liraglutide is approved as a once-daily treatment regimen and may be used in combination with metformin or a sulfonylurea in patients with insufficient glycemic control with either monotherapy or combined dual therapy. It is also approved in combination with the dual therapy of metformin and a thiazolidinedione in patients with insufficient glycemic control. Liraglutide displayed a binding potency of 61 pM (EC50= 55 pM for GLP-1) for the cloned human GLP-1 receptor.


關(guān)鍵字: 原料藥與中間體;

公司簡(jiǎn)介

一般項(xiàng)目:第二類(lèi)醫(yī)療器械銷(xiāo)售;針紡織品及原料批發(fā);服裝復(fù)試批發(fā);日用百貨銷(xiāo)售;家用電器銷(xiāo)售;第一類(lèi)醫(yī)療器械銷(xiāo)售;化工產(chǎn)品銷(xiāo)售(不含許可類(lèi)化工產(chǎn)品);五金產(chǎn)品批發(fā);計(jì)算機(jī)軟硬件及輔助設(shè)備批發(fā);化妝品批發(fā);消毒劑銷(xiāo)售(不含危險(xiǎn)化學(xué)品);專(zhuān)用化學(xué)產(chǎn)品銷(xiāo)售(不含危驗(yàn)化學(xué)品);個(gè)人衛(wèi)生用品銷(xiāo)售;金屬材料售;醫(yī)用口罩批發(fā);日用口罩(非醫(yī)用)銷(xiāo)售;醫(yī)護(hù)人員防護(hù)用品批發(fā);衛(wèi)生用品和一次性使用醫(yī)療用品銷(xiāo)售;勞動(dòng)保護(hù)用品確售;合成材料銷(xiāo)售;飼料添加劑銷(xiāo)售;藥物檢測(cè)儀器銷(xiāo)售;制藥專(zhuān)用設(shè)備銷(xiāo)售;財(cái)務(wù)咨詢(xún);信息咨詢(xún)服務(wù)(不含許可類(lèi)信息咨詢(xún)服務(wù));技術(shù)服務(wù)、技術(shù)開(kāi)發(fā)、技術(shù)咨詢(xún)、技術(shù)交流、技術(shù)轉(zhuǎn)讓、技術(shù)推廣;染料銷(xiāo)售;衛(wèi)生用品銷(xiāo)售;建筑裝飾材料銷(xiāo)售;電子辦公設(shè)備銷(xiāo)售;針紡識(shí)品銷(xiāo)售;貿(mào)易經(jīng)紀(jì);銷(xiāo)售代理;國(guó)內(nèi)貿(mào)易代理(除依法須經(jīng)批準(zhǔn)的項(xiàng)目外,憑營(yíng)業(yè)執(zhí)照依法自主開(kāi)展經(jīng)營(yíng)活動(dòng))。許可項(xiàng)目∶食品經(jīng)營(yíng)(銷(xiāo)售預(yù)包裝食品);貨物進(jìn)出口;藥品進(jìn)出口;進(jìn)出口代理;技術(shù)進(jìn)出口(依法須經(jīng)批準(zhǔn)的項(xiàng)目,經(jīng)相關(guān)部門(mén)批批準(zhǔn)方可開(kāi)展經(jīng)營(yíng)活動(dòng),具體經(jīng)營(yíng)項(xiàng)目以審批結(jié)果為準(zhǔn))。
成立日期 2003-08-13 (22年) 注冊(cè)資本 1000萬(wàn)人民幣
員工人數(shù) 1-10人 年?duì)I業(yè)額 ¥ 100萬(wàn)以?xún)?nèi)
主營(yíng)行業(yè) 中間體,醫(yī)藥原料 經(jīng)營(yíng)模式 貿(mào)易
  • 浙江凱發(fā)工貿(mào)有限公司
非會(huì)員
  • 公司成立:22年
  • 注冊(cè)資本:1000萬(wàn)人民幣
  • 企業(yè)類(lèi)型:民營(yíng)
  • 主營(yíng)產(chǎn)品:多種原料藥和中間體
  • 公司地址:西湖區(qū)蓮花峰路12號(hào)
詢(xún)盤(pán)

店內(nèi)推薦

依替巴肽 詢(xún)價(jià)
醋酸蘭瑞肽 詢(xún)價(jià)
醋酸特利加壓素 詢(xún)價(jià)

利拉魯肽相關(guān)廠(chǎng)家報(bào)價(jià)

更多
產(chǎn)品名稱(chēng) 價(jià)格   公司名稱(chēng) 報(bào)價(jià)日期
¥546
VIP4年
湖北魏氏化學(xué)試劑股份有限公司
2025-04-18
詢(xún)價(jià)
VIP3年
湖北魏氏化學(xué)試劑股份有限公司
2025-04-18
¥8000
VIP12年
湖北威德利化學(xué)科技有限公司
2025-04-17
¥6000
VIP6年
杭州信海醫(yī)藥科技有限公司
2025-04-17
詢(xún)價(jià)
VIP3年
湖北恒化科技有限公司
2025-04-17
詢(xún)價(jià)
VIP1年
哈爾濱吉象隆生物技術(shù)有限公司
2025-04-17
¥200
VIP4年
湖北健楚生物醫(yī)藥有限公司
2025-04-17
¥1250
VIP3年
湖北魏氏化學(xué)試劑股份有限公司
2025-04-17
詢(xún)價(jià)
VIP4年
武漢東康源科技有限公司
2025-04-17
詢(xún)價(jià)
VIP4年
武漢裕清嘉衡藥業(yè)有限公司
2025-04-17
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買(mǎi)數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢(xún)商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè) | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.